company background image
4DN logo

Denali Therapeutics MUN:4DN Stock Report

Last Price

€12.66

Market Cap

€1.8b

7D

0%

1Y

n/a

Updated

19 May, 2025

Data

Company Financials +

Denali Therapeutics Inc.

MUN:4DN Stock Report

Market Cap: €1.8b

4DN Stock Overview

A biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. More details

4DN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Revenue is forecast to grow 53.96% per year

Risk Analysis

Makes less than USD$1m in revenue ($0)

Shares are highly illiquid

Currently unprofitable and not forecast to become profitable over the next 3 years


Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Denali Therapeutics Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Denali Therapeutics
Historical stock prices
Current Share PriceUS$12.66
52 Week HighUS$24.41
52 Week LowUS$11.01
Beta1.49
1 Month Change15.04%
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Change-45.62%
Change since IPO-25.79%

Recent News & Updates

Recent updates

Shareholder Returns

4DNDE BiotechsDE Market
7D0%-0.8%0.5%
1Yn/a-12.7%14.4%

Return vs Industry: Insufficient data to determine how 4DN performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how 4DN performed against the German Market.

Price Volatility

Is 4DN's price volatile compared to industry and market?
4DN volatility
4DN Average Weekly Movementn/a
Biotechs Industry Average Movement5.8%
Market Average Movement6.5%
10% most volatile stocks in DE Market12.8%
10% least volatile stocks in DE Market3.1%

Stable Share Price: 4DN's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine 4DN's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2013443Ryan Wattswww.denalitherapeutics.com

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson’s and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I).

Denali Therapeutics Inc. Fundamentals Summary

How do Denali Therapeutics's earnings and revenue compare to its market cap?
4DN fundamental statistics
Market cap€1.79b
Earnings (TTM)-€405.82m
Revenue (TTM)n/a

0.0x

P/S Ratio

-4.4x

P/E Ratio

Is 4DN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4DN income statement (TTM)
RevenueUS$0
Cost of RevenueUS$395.24m
Gross Profit-US$395.23m
Other ExpensesUS$58.71m
Earnings-US$453.94m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-3.12
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did 4DN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/19 22:13
End of Day Share Price 2025/04/22 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Denali Therapeutics Inc. is covered by 25 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Caroline PalomequeBerenberg
Tazeen AhmadBofA Global Research